English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA study by UC Davis Health endocrinology researchers shows a high prevalence of thyroid cancer among transgender female veterans, the first evidence of such a disparity.
Tag: Thyroid Cancer
Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer
Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances (PFAS) and an increased risk for thyroid cancer.
A Cancer Survival Calculator Is Being Developed Using Artificial Intelligence
Researchers have developed an artificial intelligence (AI)–based tool for estimating a newly diagnosed cancer patient’s chances for surviving long term, according to a study presented at the American College of Surgeons (ACS) Clinical Congress 2023.
Adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
New study results indicate that combining two separately promising therapies for radioiodine-resistant thyroid cancer does not bring any added benefit.
June Tip Sheet from Sylvester Comprehensive Cancer Center
A world-renowned biochemist joins the Sylvester Cancer team, a global health leader strives to ensure more equitable cancer care, a recent study identifies disparities in federal cancer research funding, new targeted therapies for thyroid and other cancers are making surgery a secondary option for many patients, efforts to preserve women’s sexual health while they receive endocrine therapy for breast cancer, and more are highlighted in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
NCCN Debuts Roadmap for Improving Thyroid Cancer Care in Low- and Middle-Income Countries on World Stage
The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
How the combination of advanced ultrasound and AI could upgrade cancer diagnostics
Researchers have shown that an automated cancer diagnostic method, which pairs cutting-edge ultrasound techniques with artificial intelligence, can accurately diagnose thyroid cancer, of which there are more than 40,000 new cases every year.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
ASCO 23: Thyroid Cancer Precision Approaches That Incorporate Targeted Therapies and Other Treatments Are Changing the Surgeon’s Role
Historically, surgery was the first line of treatment for patients with thyroid cancer. Now, as targeted therapies and other new medications emerge, surgery for certain patients may become more of a secondary option if those treatments fail. This new context could potentially change how some procedures are conducted.
Study: Active Surveillance an Effective Option for Thyroid Cancer
A novel clinical trial from Cedars-Sinai Cancer shows that active surveillance is an effective treatment for many low-risk thyroid cancer patients. The study, published in JAMA Oncology, also showed for the first time that patients who opted for active surveillance experienced less anxiety than patients who underwent surgery.
AI can be used to identify benign thyroid nodules and reduce unnecessary biopsies
Artificial intelligence (AI) can be used to identify thyroid nodules seen on thyroid ultrasound that are very unlikely to be cancerous, reducing a large number of unnecessary biopsies, according to a new study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Five Facts about Thyroid Cancer
It’s thyroid cancer awareness month. Amanda M. Laird, MD, FACS, chief of endocrine surgery at Rutgers Cancer Institute of New Jersey and associate professor of surgery at Rutgers Robert Wood Johnson Medical School, shares five facts about thyroid cancer everyone should know.
American Thyroid Association Announces Award Recipients
Esteemed clinicians and researchers recognized for their contributions to American Thyroid Association, thyroid cancer and thyroid disease research.
Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
ATA Announces Women Advancing Thyroid Research Award Recipients
The American Thyroid Association (ATA) celebrates the recipients of the Women Advancing Thyroid Research Award. This award recognizes and honors the work of young women that are leading outstanding thyroid research.
Cancer cases are rising in adolescents and young adults
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
American Thyroid Association to Host Patient Education Forum
American Thyroid Association to host ATA Alliance for Thyroid Patient Education Health Forum on Saturday, November 14, 2020 from noon – 1:15pm EST. Clinicians, Patient Advocates, Patients, and Families invited to participate.
Thyroid Cancer: Small Gland, Big Impact
The thyroid is a key part of the endocrine system, a small gland at the base of your neck that produces a hormone that helps control your body’s metabolism. One of the most common and treatable cancers in the United States is thyroid cancer. Rutgers Cancer Institute expert discusses research and treatment for this disease.
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Some physicians are ordering thyroid tests for unsupported reasons
Up to one-third of physicians reported sending patients for a thyroid ultrasound for reasons not supported by clinical care guidelines, a new study led by University of Michigan Rogel Cancer Center researchers finds. Routine use of ultrasounds to detect cancerous thyroid nodules have led to a significant increase in thyroid cancer cases in recent years, although many are low-risk and unlikely to cause serious harm.
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
Survey finds physicians struggle to communicate positive prognosis to thyroid cancer patients
Despite excellent prognosis with most thyroid cancers, many newly diagnosed patients have cancer-related worry, and physicians vary in their responses to patients’ worry, according to new research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Expert Team Tackles Thyroid and Parathyroid Diseases
When the thyroid and parathyroid glands don’t work well, the entire body feels out of balance. To tackle thyroid and parathyroid diseases, Nathan Boyd, MD, recently launched the UNM Thyroid and Parathyroid Surgery Program, housed at the UNM Comprehensive Cancer Center, to offer state-of-the-art treatments for these diseases.
Study provides new understanding of mitochondria genome with potential for new avenues of treatment for multiple cancers
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.
Elevated Leukemia Incidence Is Found in World Trade Center Rescue and Recovery Workers
Responders who worked at the World Trade Center site after the attacks on September 11, 2001, have an increased overall cancer incidence compared to the general population, particularly in thyroid cancer, prostate cancer, and, for the first time ever reported, leukemia, according to a Mount Sinai study published in JNCI Cancer Spectrum in January.
Researchers identify new gene mutation in familial thyroid cancers
Researchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer.
Thyroid Cancer Presentations at American Thyroid Association: 89th Meeting
The American Thyroid Association will hold its 89th Annual Meeting on October 30-November 3, 2019, at the Sheraton Grand Chicago in Chicago, Illinois. In addition to hearing major speeches and awards, attendees can view the following oral presentations on thyroid cancer.###The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community.